ライフサイエンスコーパス: GERD

1 GERD can influence patients' health-related quality of l

2 GERD has high prevalence and is the major risk factor fo

3 GERD Health-Related Quality of Life scores improved from

4 GERD is believed to cause nonesophageal symptoms, such a

5 GERD is common among this study population, with a preva

6 GERD is highly prevalent in southern India.

7 GERD symptoms alone identified patients with BE with an

8 GERD was diagnosed by Los Angeles classification A-D and

9 nt-reported symptoms: dysphagia (P = .0012), GERD (P = .0001), and nausea/vomiting (P < .0001).

10 Among 942,071 GERD patients, 48,863 underwent surgery and 893,208 did

11 Among 814,230 GERD patients, 47,016 (5.8%) underwent antireflux surger

12 hundred and five participants, including 285 GERD and 220 Non-GERD participants participated in the s

13 ern India during 2010 and early 2011 using a GERD questionnaire (GerdQ).

14 ve esophagitis or nonerosive but pH-abnormal GERD) or eosinophilic esophagitis than in patients witho

15 ndividuals has features that protect against GERD-induced damage, compared with European American ind

16 easured biomarkers between the achalasia and GERD groups suggesting that luminal stasis does increase

17 a polygenic overlap between GERD and BE, and GERD and EA.

18 was recurrence of GERD, which was defined as GERD combined with a reflux index greater than 4 on pH m

19 tion of 77% (s.e. = 24%, P = 0.0012) between GERD and BE and 88% between GERD and EA (s.e. = 25%, P =

20 0.0012) between GERD and BE and 88% between GERD and EA (s.e. = 25%, P = 0.0004) was estimated using

21 D, and the extent of genetic overlap between GERD and BE or EA.

22 and supports for a polygenic overlap between GERD and BE, and GERD and EA.

23 Loci discovery is greatest with a broad GERD definition (including cases defined by self-report

24 n the center of tumorigenic events caused by GERD is repeated damage of esophageal tissues by the ref

25 risk of tumorigenic transformation caused by GERD.

26 can benefit patients with well-characterized GERD.

27 ere found in 44.2 % and 26.8 % had confirmed GERD.

28 h April 2017, of 280 patients with confirmed GERD.

29 ported that early results of GBP can control GERD.

30 tion of the Grand Ethiopian Renaissance Dam (GERD) is completed, the Nile will have two of the world'

31 prototype device, measurements of MI detect GERD with higher levels of specificity and positive pred

32 n masala chewing were more likely to develop GERD compared with those abstained from the habit (multi

33 edisposition increase the risk of developing GERD.

34 the prevalence of gastroesophageal disease (GERD) and extraesophageal manifestations among undergrad

35 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI, 1.4-2.6), dyspepsia (RR, 3.3; 95

36 factor in gastro-esophageal reflux disease (GERD) and as a target for GERD treatment.

37 , including gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE).

38 standing of gastroesophageal reflux disease (GERD) and its complications.

39 stations of gastroesophageal reflux disease (GERD) and to compare the most recent technological advan

40 c tests for gastroesophageal reflux disease (GERD) are suboptimal and do not accurately and reliably

41 nagement of gastroesophageal reflux disease (GERD) commonly starts with an empiric trial of proton pu

42 treated for gastroesophageal reflux disease (GERD) during infancy.

43 f recurrent gastroesophageal reflux disease (GERD) have been reported.

44 with acute gastroesophageal reflux disease (GERD) have not been studied prospectively in humans.

45 documented Gastro-Esophageal Reflux Disease (GERD) in 53.4% of patients.

46 evalence of gastroesophageal reflux disease (GERD) in Africa is not known but is believed to be incre

47 evalence of gastroesophageal reflux disease (GERD) in the United States.

48 Gastroesophageal reflux disease (GERD) increases EAC risk, but whether antireflux surgery

49 Gastroesophageal reflux disease (GERD) is a common comorbidity among patients with asthma

50 gested that gastroesophageal reflux disease (GERD) is a risk factor for developing rhinitis/rhinosinu

51 nagement of gastroesophageal reflux disease (GERD) is being employed increasingly.

52 Gastroesophageal reflux disease (GERD) is caused by gastric acid entering the esophagus.

53 ogenesis of gastroesophageal reflux disease (GERD) is complex and involves changes in reflux exposure

54 Gastroesophageal reflux disease (GERD) is defined by recurrent and troublesome heartburn

55 Gastroesophageal reflux disease (GERD) is prevalent worldwide, particularly in developed

56 Gastro-esophageal reflux disease (GERD) is suggested to be associated with some socio-demo

57 Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal disorder in

58 Gastroesophageal reflux disease (GERD) is the strongest known risk factor for esophageal

59 Refractory gastroesophageal reflux disease (GERD) reduces quality of life and creates significant fi

60 Gastroesophageal reflux disease (GERD) seems to increase the risk of laryngeal and pharyn

61 valence of gastro-esophageal reflux disease (GERD) varies widely around the world.

62 urements of gastroesophageal reflux disease (GERD) would improve management of patients suspecting of

63 rome (IBS), gastroesophageal reflux disease (GERD), and overactive bladder syndrome (OBS), as well as

64 ndications: gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and non-steroidal anti-

65 evalence of gastroesophageal reflux disease (GERD), esophagitis, and Barrett's esophagus (BE) after s

66 Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syn

67 duration of gastroesophageal reflux disease (GERD), using data from a randomly selected 50% of patien

68 Gastroesophageal reflux disease (GERD), which leads to acid reflux into the esophagus, is

69 evalence of gastroesophageal reflux disease (GERD), yet esophageal adenocarcinoma (EAC) disproportion

70 more in the Gastroesophageal Reflux Disease (GERD)-Health Related Quality of Life score (range, 0 to

71 reatment of gastroesophageal reflux disease (GERD).

72 (EoE), and gastroesophageal reflux disease (GERD).

73 otherapy in gastroesophageal reflux disease (GERD).

74 reatment of gastroesophageal reflux disease (GERD).

75 symptoms of gastroesophageal reflux disease (GERD).

76 early-stage gastroesophageal reflux disease (GERD).

77 tients with gastroesophageal reflux disease (GERD).

78 is chronic gastroesophageal reflux disease (GERD).

79 tients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 women) without troublesome regurgi

80 with proven gastroesophageal reflux disease [GERD]), to document physiologic levels of esophageal aci

81 mitting to lifelong PPIs to help distinguish GERD from a functional syndrome.

82 based cohort study of adults with documented GERD in 1980 to 2014.

83 The existence and treatment of TSE during GERD/HH surgery is controversial.

84 LRYGB allows to obtain an effective GERD symptom amelioration and a reduction in acid exposu

85 Respondents meeting the criteria for either GERD, FD or IBS have significantly higher odds of report

86 evidence, anti-reflux surgery and endoscopic GERD treatment modalities have no therapeutic benefit in

87 ound that 35.1% of those who had experienced GERD symptoms were currently on therapy (55.2% on PPIs,

88 phenotypic variance of 7% (95% CI 3-11%) for GERD explained by all the genotyped SNPs.

89 Their place in the treatment algorithm for GERD will be better defined when important clinical para

90 he frequency and duration of GERD (AuROC for GERD, 0.579 vs range for other tools, 0.660-0.695), and

91 the first evidence for a polygenic basis for GERD and supports for a polygenic overlap between GERD a

92 tient with the addition of an H2-blocker for GERD, or addressing potentially serious underlying cause

93 capacity in adults meeting the criteria for GERD, FD and IBS, respectively, and in individuals who m

94 (7.6%) satisfied the diagnostic criteria for GERD, while 107 (3.0%) had GERD associated with signific

95 and minimally invasive surgical devices for GERD therapy are a promising alternative to proton pump

96 7.7 kg/m2] were consecutively evaluated for GERD irrespectively of related symptoms, before the oper

97 Our results map genes for GERD and related traits and uncover potential new drug t

98 independent genome-wide significant loci for GERD.

99 lication are proven treatment modalities for GERD.

100 d surgery are the main treatment options for GERD.

101 follow-ups based on objective parameters for GERD are missing.

102 The MI pattern for GERD was easily distinguished from that of EoE: in patie

103 Only age showed significant predictor for GERD.

104 and receiving primary antireflux surgery for GERD in 2000 to 2012 with follow-up through 2014, and th

105 ts undergoing minimally invasive surgery for GERD/HH, the distance between the endoscopically-localiz

106 al reflux disease (GERD) and as a target for GERD treatment.

107 Many diagnostic tests for GERD have been developed over the past decades.

108 ical, surgical, and endoscopic therapies for GERD.

109 nd minimally invasive surgical therapies for GERD.

110 ting to further confirm MSA as treatment for GERD.

111 remains the standard surgical treatment for GERD.

112 Using a population-based survey, we found GERD symptoms to be common: 2 of 5 participants have had

113 American individuals might protect them from GERD-induced damage and contribute to the low incidence

114 Probabilities of assignment to each group (GERD, non-GERD, or EoE) were estimated using multinomial

115 stic criteria for GERD, while 107 (3.0%) had GERD associated with significant impairment of quality o

116 ipants was 647, out of which 212 (32.8%) had GERD.

117 s to be common: 2 of 5 participants have had GERD symptoms in the past and 1 of 3 had symptoms in the

118 icipants, 32,878 (44.1%) reported having had GERD symptoms in the past and 23,039 (30.9%) reported ha

119 (67.9%) and 86 (32.1%) females and male had GERD respectively (p = 0.13).

120 Thereafter those who had GERD were further questioned and examined for extra-oeso

121 y than typical symptoms when the patient has GERD.

122 Patients were classified as having GERD (erosive esophagitis or abnormal pH; n = 24), EoE (

123 the past and 23,039 (30.9%) reported having GERD symptoms in the past week.

124 The frequency of overlap with IBS, GERD, and OBS were determined for the whole group and fo

125 tudy experienced improvement or no change in GERD regardless of procedure.

126 orted symptom relief, with no differences in GERD symptoms or dysphagia.

127 rgoing SG experienced similar improvement in GERD symptoms when compared to RYGB (30.4% vs 30.8%, p =

128 retion layer and EGJ was 2.6 times longer in GERD compared to HS (p = 0.012).

129 dyspeptic patients, SE detected more MCE in GERD than in non-GERD patients and in the control group.

130 MCE in GERD was significantly higher (51.45 %) than in non-GERD

131 (193 ml to 100 ml, in HS, 227 ml to 94 ml in GERD; p < 0.01) and thickness of the acid layer (26 mm t

132 ios (HRs) with 95% CIs, compared EAC risk in GERD patients with antireflux surgery with those with no

133 ibution and acidity of gastric secretions in GERD and healthy subjects (HS).

134 yer on top of gastric contents is similar in GERD patients and HS; however contact between the layer

135 reported benefit of endoscopic therapies in GERD.

136 antireflux surgery and medical treatment in GERD patients without known Barrett's esophagus (IRR 0.9

137 We conduct a large GERD GWAS meta-analysis (80,265 cases, 305,011 controls)

138 flux disease, cough, aspiration, laryngitis, GERD, GORD, endoscopy, manometry, pH monitoring, proton

139 flux disease, cough, aspiration, laryngitis, GERD, GORD, endoscopy, manometry, pH monitoring, proton

140 nctional diseases that overlap with or mimic GERD can also be treated with neuromodulators (primarily

141 gender, BMI, smoking, asthma, and nocturnal GERD were calculated.

142 valuating the relationship between nocturnal GERD and noninfectious rhinitis (NIR).

143 0.001) and with the development of nocturnal GERD.

144 ased, 10-year study indicates that nocturnal GERD was a risk factor for noninfectious rhinitis/rhinos

145 acco smoke, and asthma, those with nocturnal GERD in 1999 (>/=3 episodes of nocturnal gastroesophagea

146 participants, including 285 GERD and 220 Non-GERD participants participated in the study.

147 .01) among patients with GERD, EoE, and non-GERD.

148 ities of assignment to each group (GERD, non-GERD, or EoE) were estimated using multinomial logistic

149 were excluded for other reasons, 23 had non-GERD esophageal disorders, and 99 had functional heartbu

150 s significantly higher (51.45 %) than in non-GERD (32.7 %) (p = 0.047) and in the control group (20.5

151 ts, SE detected more MCE in GERD than in non-GERD patients and in the control group.

152 stal and proximal esophagus; n = 21), or non-GERD (normal results from esophagogastroduodenoscopy and

153 to identify patients with GERD, EoE, or non-GERD.

154 Patients with non-GERD had higher MI values along all measured segments.

155 oE with an AUC = 0.84, and patients with non-GERD with an AUC = 0.83 in the development cohort.

156 surgery patients was compared to nonoperated GERD patients using multivariable Cox regression, provid

157 sk after antireflux surgery with nonoperated GERD patients, including 7 studies of patients with Barr

158 Risk factors for complications of GERD include advanced age, male sex, white race, abdomin

159 s to characterize the longitudinal course of GERD and of associated erosive tooth wear, as well as fa

160 Diagnosis of GERD was by means of the gastroesophageal reflux disease

161 alues, whereas 32 (group B) had diagnosis of GERD: 23 had acidic reflux, whereas 9 had combined reflu

162 s with BE than the frequency and duration of GERD (AuROC for GERD, 0.579 vs range for other tools, 0.

163 more accurate than frequency and duration of GERD in identifying individuals at risk for neoplastic B

164 Given the significant effect of GERD on quality of life, further research and developmen

165 nd useful information on the epidemiology of GERD in Iran for policy-makers and health care providers

166 conducted to investigate the epidemiology of GERD in Iran.

167 wever, long-term instrumental evaluations of GERD after LRYGB are not available.

168 Risk factors of GERD (represented by odds ratios) were age 1.014(95% CI:

169 vestigate the prevalence and risk factors of GERD in a general population of southern India.

170 masala chewing appear to be risk factors of GERD symptoms for the studied population.

171 determine the prevalence and risk factors of GERD, and its degree of overlap with dyspepsia and irrit

172 wed symptomatic and objective improvement of GERD with the device therapies.

173 The incidence of GERD decreased in 34 (64%) and 21 (40%) patients at E1 a

174 The clinical management of GERD influences the lives of many individuals and is res

175 OUND DATA: Extraesophageal manifestations of GERD include cough, laryngopharyngeal reflux (LPR), and

176 4, 2.73) were associated with higher odds of GERD, while higher educational level (OR = 0.53, 95%CI =

177 .81) were positively associated with odds of GERD, while higher educational level (OR = 0.55, 95%CI =

178 0.91) was associated with decreased odds of GERD.

179 30, 0.94) were associated with lower odds of GERD.

180 Overlap of GERD with dyspepsia and/or IBS was observed in over 50%

181 GERD symptoms in the past and persistence of GERD symptoms (heartburn or regurgitation 2 or more days

182 Presence of GERD was defined as a score of >/= 8.

183 low LES pressure would mark the presence of GERD.

184 This study showed a high prevalence of GERD in Iran.

185 Several studies have shown the prevalence of GERD in Iranian population, but their evidence is contra

186 It is estimated that the prevalence of GERD in the United States is approximately 20% and that

187 The prevalence of GERD in this study is 7.6%.

188 n-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite use o

189 The prevalence of GERD symptoms appeared to increase until 1999.

190 , weekly, monthly, and overall prevalence of GERD symptoms in Iranian population was 5.64% (95%CI [co

191 Primary outcomes were prevalence of GERD symptoms in the past and persistence of GERD sympto

192 The prevalence of GERD was 22.2 % (238/1072) in southern India, and was mo

193 The primary outcome was prevalence of GERD, esophagitis, and BE after SG.

194 The postoperative prevalence of GERD, esophagitis, and BE following SG is significant.

195 ndergoing LF (37%) experienced recurrence of GERD compared to those undergoing OF (7%); risk ratio fo

196 The main outcome measure was recurrence of GERD, which was defined as GERD combined with a reflux i

197 cleotide polymorphisms (SNPs) to the risk of GERD, and the extent of genetic overlap between GERD and

198 jects had a dose-dependent increased risk of GERD, compared to those with body mass index less than 2

199 level appeared to have an increased risk of GERD.

200 e is substantial overlap between symptoms of GERD and those of eosinophilic esophagitis, functional d

201 viduals experiencing overlapping symptoms of GERD, FD and IBS.

202 es that individuals experiencing symptoms of GERD, FD or IBS report poor self-rated health as well as

203 modified Frequency Scale for the Symptoms of GERD.

204 d examined for extra-oesophageal symptoms of GERD.

205 Surgical treatment of GERD does not seem to reduce EAC risk.

206 t have a positive effect in the treatment of GERD in an urban population of Iran.

207 Future approaches to treatment of GERD include potassium-competitive acid blockers, reflux

208 ithout heartburn or regurgitation typical of GERD.

209 We analyze the value of GERD diagnostic tests in evaluation of these troublesome

210 with erosive tooth wear and oligosymptomatic GERD receiving esomeprazole for one year, erosive tooth

211 emographic or lifestyle factors with data on GERD symptoms identified patients with BE with an AUC of

212 Therefore, effective measures on GERD-related factors such as lifestyle can be among the

213 At least one GERD symptom was present in 74 % of patients with 41 % r

214 on only demographic or lifestyle factors or GERD symptoms identified patients with BE or EAC with AU

215 d troublesome heartburn and regurgitation or GERD-specific complications and affects approximately 20

216 Overlapping GERD symptoms were found in 44.2 % and 26.8 % had confir

217 e prevalence of GERD symptoms and persistent GERD symptoms despite use of proton pump inhibitors (PPI

218 ants taking daily PPIs, 54.1% had persistent GERD symptoms.

219 ients with EA are at high risk of persistent GERD and BE.

220 sis found that the increase of postoperative GERD after sleeve (POGAS) was 19% and de novo reflux was

221 tional heartburn, the exception being proven GERD that overlaps with functional heartburn.

222 I therapy in patients with history of proven GERD (ie, positive pH study, erosive esophagitis, Barret

223 Overlap of functional heartburn with proven GERD is diagnosed according to Rome IV criteria when hea

224 controlled trial (RCT) patients with proven GERD were eligible and assigned by central randomization

225 nctional heartburn that overlaps with proven GERD.

226 s, and 16% require reoperation for recurrent GERD and/or dysphagia.

227 causing significant weight loss, GBP reduces GERD symptoms, improves reflux esophagitis, and decrease

228 Gastro-esophageal reflux (GERD) post-SG is a critical issue due to symptom severit

229 ar have significant gastroesophageal reflux (GERD), despite minor reflux symptoms.

230 with proton pump inhibitor (PPI)-refractory GERD were randomized to CNF or LNF.

231 are needed for patients with PPI-refractory GERD symptoms.

232 randomized trial of patients with refractory GERD, adding 1500 mg IW-3718 to label-dose PPIs signific

233 Questions regarding GERD were developed based on the Montreal definition.

234 ) >=15 years after treatment], or for severe GERD [HR 1.56 (95% CI 1.11-2.20) 1-<5 years and HR 1.57

235 decrease was found for patients with severe GERD (esophagitis or Barrett esophagus) after surgery [S

236 Analyses of patients with severe GERD (reflux esophagitis or Barrett esophagus) showed si

237 nts with Barrett's esophagus and symptomatic GERD should take a long-term PPI.

238 gnostic of gastroesophageal reflux symptoms (GERD).

239 discriminating BE with early neoplasia than GERD frequency and duration alone (AuROC, 0.667; P < .01

240 nvention of the esophagoscope confirmed that GERD was a premorbid condition.

241 argest dams-the High Aswan Dam (HAD) and the GERD-in two different countries (Egypt and Ethiopia).

242 follow-up, ranging from 12 to 58 months, the GERD-HRQL score was within normal limits in all patients

243 Further, 91% of the GERD risk-increasing alleles also increase BE and/or EA

244 oms and proton pump inhibitor (PPI) therapy, GERD-Health Related Quality of Life scores, esophageal a

245 ion should be directed to FD, in addition to GERD, as a comorbidity of the digestive system in patien

246 and 99 had functional heartburn (not due to GERD or other histopathologic, motility, or structural a

247 those who lack an obvious predisposition to GERD (eg, central obesity, large hiatal hernia).

248 toms as well as specific symptoms related to GERD and OBS.

249 The development of BE is related to GERD history.

250 te children with EoE and PPI-REE relative to GERD, supporting the relationship between these 2 groups

251 in 31.8% of patients routinely submitted to GERD/HH surgery.

252 g in urban community were more vulnerable to GERD than those in rural community (multivariate-adjuste

253 riteria of at least a 50% reduction in total GERD Health-Related Quality of Life score compared with

254 I 0.42-1.39) compared with medically treated GERD patients.

255 itivity analysis for prevalence of all types GERD, heartburn and regurgitation symptoms by removing a

256 Typical GERD symptoms are often sufficient to determine the diag

257 Patients with typical GERD symptoms can be medicated empirically with a proton

258 actice Advice 2: Patients with uncomplicated GERD who respond to short-term PPIs should subsequently

259 We used a validated GERD survey with symptom scores ranging from 0 (no sympt

260 stric bypass is the procedure of choice when GERD and morbid obesity coexist.

261 nts with achalasia, 22 with EoE, and 20 with GERD (symptoms plus esophagitis or + reflux study) were

262 ake were independent factors associated with GERD.

263 We performed clinical evaluation with GERD-HRQoL questionnaire, upper endoscopy, esophageal ma

264 socio-demographic and lifestyle factors with GERD in participants referred to a teaching hospital in

265 surgery group with the nonsurgery group with GERD [HR 1.71 (95% CI 1.26-2.33) 1-<5 years and HR 1.69

266 ased cohort study including individuals with GERD from all 5 Nordic countries in 1964-2014.

267 ion of minimal change esophagitis (MCE) with GERD is controversial.

268 controlled, phase 4 study, outpatients with GERD were randomly allocated to either group 1 (omeprazo

269 were signi fi cantly lower in patients with GERD (erosive esophagitis or nonerosive but pH-abnormal

270 Best Practice Advice 1: Patients with GERD and acid-related complications (ie, erosive esophag

271 Patients with GERD and hiatal hernias </=2 cm were randomly assigned t

272 in detecting MCL in dyspeptic patients with GERD compared with patients without GERD by GerdQ or by

273 The pattern of MI in patients with GERD differed from that in patients without GERD or pati

274 with eosinophilic esophagitis; patients with GERD had low MI closer to the squamocolumnar junction, a

275 sulted in esophageal stasis in patients with GERD or SERD.

276 Most patients with GERD present with heartburn and effortless regurgitation

277 Patients with GERD symptoms combined with warning symptoms of malignan

278 was an effective treatment for patients with GERD symptoms, particularly in those with persistent reg

279 Approximately 30% of patients with GERD who receive label-dose proton pump inhibitors (PPIs

280 mocolumnar junction identified patients with GERD with an AUC = 0.67, patients with EoE with an AUC =

281 significantly (P < .01) among patients with GERD, EoE, and non-GERD.

282 o be safe and able to identify patients with GERD, EoE, or non-GERD.

283 inguished from that of EoE: in patients with GERD, MI values were low in the distal esophagus and nor

284 and healing of esophagitis in patients with GERD.

285 sia and IBS exists in Nigerian patients with GERD.

286 a greater extent than PPIs in patients with GERD.

287 Nissen fundoplication (LNF) in patients with GERD.

288 usion of acid than controls or patients with GERD.

289 hoice in bariatric surgery for patients with GERD.

290 d antireflux surgery, and 41% presented with GERD symptoms, although only 28% were receiving medical

291 extraesophageal symptoms found in those with GERD were, dysphagia, coated tongue, nocturnal cough, xe

292 geal manifestations were found in those with GERD.

293 nts with GERD compared with patients without GERD by GerdQ or by endoscopy with 24-h pH monitoring (P

294 ophilic esophagitis than in patients without GERD or patients with achalasia (P < .001).

295 GERD differed from that in patients without GERD or patients with eosinophilic esophagitis; patients

296 compared the rates of improved and worsened GERD symptoms after SG and RYGB.

297 Worsening GERD was the most common presenting symptom in 79 (61.7%

298 patients reported higher rates of worsening GERD symptoms when compared to RYGB, the majority of pat

299 precise prevalence of new-onset or worsening GERD after SG is controversial.

300 Development of new-onset or worsening GERD symptoms following bariatric surgery varies by proc